Research programme: heat shock protein 90 inhibitors - Locus

Drug Profile

Research programme: heat shock protein 90 inhibitors - Locus

Alternative Names: Heat shock protein 90 inhibitors research programme - Locus; HSP90 inhibitors - Locus

Latest Information Update: 21 Jan 2010

Price : $50

At a glance

  • Originator Locus Pharmaceuticals
  • Developer Locus Pharmaceuticals; National Cancer Institute (USA)
  • Class
  • Mechanism of Action Heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 21 Jan 2010 This research programme is still in active development
  • 13 Jan 2005 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top